Skip to main content

Alternative Pain Therapy for Breast, Prostate and Lung Cancer

Alternative Pain Therapy for Breast, Prostate and Lung Cancer

MIAMI--(Healthcare Sales & Marketing Network)-- Bio-Nucleonics? lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron?, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium acts similar to calcium and is preferentially taken up in osteoblastic tissue while the unabsorbed isotope is excreted in the urine the first 2 to 3 days following injection, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Strontium Chloride Sr-89 Injection USP can be replaced or used in combination with opiate based drugs like Oxycotin?, Morphine, Percocet? as well as cancer therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.

?For more than a decade, Bio-Nucleonics has been providing us with Strontium Chloride Sr-89 for the palliation of painful bone metastases. Strontium has been a God-send and has proved invaluable in providing patients with dramatic pain relief from the debilitating chronic pain of metastatic bone cancer without the side effects caused by opioids.? stated Dr. Ernie Meth, of Temecula Valley Nuclear Medicine.

ABOUT BIO-NUCLEONICS:

Bio-Nucleonics, Inc., is a privately-held, life sciences company, specializing in the development, manufacture and marketing of radiopharmaceuticals, medical devices and imaging agents for the detection and treatment of oncological, cardiovascular, and neurological diseases. The Company has a product development pipeline including several new drug applications with products in various stages of development. The Company's business strategy is to capitalize on its proven expertise targeted to improving patient care and quality-of-life.


View the original article here

Labels:

Popular posts from this blog

Analysis: Life saving lung cancer test to set off cost debate

By Bill Berkrot NEW YORK | Wed Jun 29, 2011 6:07pm EDT NEW YORK (Reuters) - A landmark study showing that routine lung screening of heavy smokers and former smokers using low dose CT scans could save thousands of lives is sure to set off a fierce debate about the cost of such testing on an overburdened healthcare system. The U.S. National Cancer Institute studied more than 53,000 people between the ages of 55 and 74 deemed at high risk of developing lung cancer. It found that screening with the three-dimensional X-rays cut deaths by 20 percent. Details of the study and a discussion of its implications were published on Wednesday in the New England Journal of Medicine, lending additional weight to initial findings that were released in November. The discussion noted that radiologists using more advanced CT equipment than was available for the study could lead to an even larger reduction in lung cancer deaths. At the same time, the potential for many more false positive results could ri...
Read more

Who should get a CT scan to screen for lung cancer?

By Jenifer Goodwin HealthDay Reporter THURSDAY, June 30 (HealthDay News) -- Annual low-dose CT scans cut the death rate from lung cancer by 20% in heavy smokers and formerly heavy smokers, compared to those who get annual chest X-rays, according to the results of a major National Cancer Institute study released on Wednesday. Experts are calling the findings a major advance in efforts to combat lung cancer deaths. By catching the cancer early, the tumors can be removed surgically -- hopefully before they've spread and become very difficult to cure. "This is a momentous time in the history of public health research," said Dr. Otis Brawley, chief medical officer of the American Cancer Society. "The NLST [National Lung Screening Trial] is the best-designed and best-performed lung cancer screening study in history." Yet the findings raise as many questions as they answer, said Dr. Harold Sox, a professor emeritus of medicine at Dartmouth Medical School who wrote an...
Read more

Lung Cancer - A Look at the Numbers

It is a known fact that lung cancer is the second leading cause of death and the biggest cause of cancer deaths in both sexes in the West. It accounts for about 30% of all deaths from cancer. The unfortunate reality is that many of those deaths could have been prevented -- fully 85% of all lung cancers are caused by smoking. This includes those who breathe in second-hand smoke from others in the vicinity. If everyone were to give up smoking, the incidence of lung cancer would drop dramatically. After smoking, radon exposure is the second most common cause of lung cancer in America. The US Environmental Protection Agency estimates that about 21,000 deaths are caused every year by radon exposure. Among various ethnic groups, the incidence of lung cancer is highest among African Americans. This is because of a high cultural propensity among this group to take up the smoking habit. This is also one of the deadliest forms of cancer around. To give some comparative statistics, the five-year ...
Read more